Philipp Janser
Basel, BS 4002, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Discovery of NP3-742: A Structurally Diverse NLRP3 Inhibitor Identified through an Unusual Phenol Replacement.
Journal: Journal of medicinal chemistry
Published: October 15, 2025
Discovery of NP3-253, a Potent Brain Penetrant Inhibitor of the NLRP3 Inflammasome.
Journal: Journal of medicinal chemistry
Published: November 22, 2024
Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors.
Journal: Journal of medicinal chemistry
Published: January 04, 2024
Discovery and Optimization of Novel SUCNR1 Inhibitors: Design of Zwitterionic Derivatives with a Salt Bridge for the Improvement of Oral Exposure.
Journal: Journal of medicinal chemistry
Published: August 29, 2020
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Journal: Journal of medicinal chemistry
Published: February 22, 2020
Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.
Journal: ACS medicinal chemistry letters
Published: July 15, 2019
Pathophysiological Consequences of a Break in S1P1-Dependent Homeostasis of Vascular Permeability Revealed by S1P1 Competitive Antagonism.
Journal: PloS one
Published: August 08, 2016
An oral sphingosine 1-phosphate receptor 1 (S1P(1)) antagonist prodrug with efficacy in vivo: discovery, synthesis, and evaluation.
Journal: Journal of medicinal chemistry
Published: October 17, 2012
A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis.
A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis.
Journal: Chemistry & biology
Published: April 20, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026